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Edited by Lukas HuberAbstract The developmentally regulated architectural tran-
scription factor, high mobility group A2 (HMGA2), is involved
in growth regulation and plays an important role in embryogen-
esis and tumorigenesis. Little is known, however, about its
downstream targets. We performed a search for genes of which
expression is strongly altered during embryonic development in
two HMGA2-deﬁcient mouse strains, which display a pygmy-
phenotype, as compared to wild-type mice. We found that the
insulin-like growth factor II mRNA-binding protein 2 gene
(IMP2), but not its family members IMP1 and IMP3, was
robustly downregulated in mutant E12.5 embryos. Furthermore,
we show that wild-type HMGA2 and its tumor-speciﬁc truncated
form have opposite eﬀects on IMP2 expression. Our results
clearly indicate that HMGA2 diﬀerentially regulates expression
of IMP family members during embryogenesis.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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High mobility group A2 (HMGA2) is a member of the
HMGA gene family [1,2]. The HMGA proteins contain three
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II; RRM, RNA recognition motif
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.05.075rich stretches in the narrow minor groove of DNA [3], and an
acidic C-terminal tail. Although these proteins possess a clas-
sical transcription factor structure, they do not have tran-
scriptional activation capacity by themselves. HMGA proteins
play a critical role in organizing the assembly and stabilization
of nucleo-protein transcriptional complexes (enhanceosomes)
at the level of enhancer- or promoter-regions, resulting in in-
duction or repression of transcription. They are classiﬁed as
architectural transcription factors (reviewed in [4,5]). The best
characterized example of how HMGA proteins can modulate
gene expression is provided by studies describing the expres-
sion regulation of the interferon-b gene [6]. Recently, it was
shown that HMGA2 modulates the promoter activity of the
DNA repair gene ERCC1 [7] and of the cyclin A gene [8].
In mice, HMGA2 expression is high during early develop-
ment but barely detectable in adult tissues [9]. Consistent with
its growth-regulatory role is the pygmy phenotype in mice in
which the HMGA2 gene is homozygously inactivated [10].
HMGA2 is disrupted and aberrantly expressed in many tumor
types making this gene probably the most frequently rear-
ranged gene in human neoplasias (reviewed in [11,12]). We
identiﬁed the HMGA2 gene as the gene that is disrupted by
12q15 chromosomal rearrangements observed in a variety of
commonly occurring benign solid tumors [13,14]. Disruption
of the gene in these tumors usually results in the expression of
a truncated protein only containing the DNA-binding domains
of wild-type HMGA2. In contrast to the expression of aber-
rant forms of HMGA2 in benign tumors, overexpression of
wild-type HMGA2 has been reported in various malignant
tumors, such as breast cancer [15] and pancreatic tumors [16].
Although HMGA2 has been clearly implicated in cell pro-
liferation and tumorigenesis, the underlying molecular and bi-
ological events involved in these phenomena still need further
unraveling. One way to address this issue is to search for genes
of which the expression is regulated by this architectural tran-
scription factor, such as recently described for the structurally
related HMGA1 gene [17]. We have performed expression
proﬁling experiments using embryos of the spontaneous pg/pg
mouse mutant, which is HMGA2-deﬁcient, and correspondingation of European Biochemical Societies.
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of HMGA2 on the expression of the genes encoding the various
members of the insulin-like growth factor II (IGF-II) mRNA-
binding protein (IMP) family. We have validated our results
using the genetically engineered HMGA2-speciﬁc knockout
mouse strain and a cell-based system.2. Materials and methods
2.1. Mouse strains and genotyping
Mouse strains included C3Wf.Cg-Hmga2pg/BmJ (Jackson Labora-
tories), which is a spontaneous pg/pg mutant, and C57BL-129SV in
which the HMGA2 allele was inactivated by gene targeting [10].
HMGA2-genotyping was performed as described in [18].
2.2. RNA extraction and Northern blot analysis
Total RNA was isolated from whole mouse embryos using the
guanidine isothiocyanate method [19]. RNA from NIH/3T3 cells was
isolated using the RNeasy total RNA isolation kit (Qiagen), according
to the manufacturer’s conditions. Northern blot analysis was per-
formed as described in [20]. After exposure to a PhosphoImager screen
(Molecular Dynamics), signals were detected using a Typhoon 9200
scanner (Amersham Biosciences) and quantiﬁed using ImageQuant 5.2
software (Molecular Dynamics).
2.3. Microarray analysis
Microarray analysis was performed at the VIB MicroArray Facility
(www.microarrays.be). Arrays with ArrayExpress Accession Nos. A-
MEXP-4 and A-MEXP-6 (www.ebi.ac.uk/arrayexpress/) were hy-
bridized with pooled RNAs from 10 E12.5 pg/pg or 10 corresponding
wild-type mouse embryos, as molecular probes. Antisense RNA was
ampliﬁed using a modiﬁed protocol of in vitro transcription as de-
scribed [21]. Cy3 and Cy5 labeling protocols were done as described (P-
MEXP-578 and P-MEXP-579). Hybridization and scanning of the
slides was performed as described (P-MEXP-580 and P-MEXP-582).
For image analysis, ArrayVision was used (Imaging Research Inc).
Spot intensities were measured as artifact-removed total intensities
(ARVol) subtracted with median intensity of the local background of
each spot. For each gene, ratios of red (Cy-5) over green (Cy-3) in-
tensities (I) were calculated and normalized via a running median of
the log 10 ratios (log 10 (ICy-5/ICy-3)) over the log 10 total intensity
(log 10 (ICy-5  ICy-3)). Mean ratios were calculated from the dupli-
cate spots and represented as average non-logarithmic ratios in the
results. Statistical analysis was performed as described in [22].
2.4. Primers
The following primers were used: IMP1up1: 50-GTAGAAA-
GTTTGCGGCTC-30; IMP1up2: 50-GACTACGAATTCACCAT-
GAACAAGCTTTACATCGGCAAC-30; IMP1low1: 50-TATCTTG-
GAGCCAATGGGAC-30; IMP1low2: 50-CTGATGGCGGCCGCT-
CACTTCCTCCGAGCCTG-30; IMP2up1: 50-CTCTCGGGAAG-
AC-30; IMP2up2: 50-GACTACGAATTCCGGATGATGAACAAG-
CTGTAC-30; IMP2low1: 50-TCAGGTGTTGGGAGGGCTAC-30;
IMP2low2: 50-CTGATGGCGGCCGCTCACTTGCTGCGCTGTG-
30; IMP3up3: 50-TCCAGAGTTTATCAAGTGCTG-30; IMP3up5:
50-GACTACGAATTCCGTGACCAGACACCTGATGAG-30; IM-
P3low3: 50-CTTCCCTTAGGTTATCCATG-30; IMP3low5: 50-CTG-
ATGGCGGCCGCACAGGAGACAACAGCTCTTC-30; HMGA2-
up3: 50-GACTACAGATCTAGGCAGGATGAGCGCACG-30; HM
GA2low3: 50-GTAGTCGAATTCGGTAGAAATCGAACGTTGC-
G-30; HMGA2low5: 50-GTAGTCGAATTCTTACCATTTCCTAGG-
TCTGCCTC-30; actin-up: 50-ACTATTGGCAACGAGCGGTTC-30;
and actin-low: 50-GGAGCCACCGATCCACACAGA-30.
2.5. Plasmids
Mouse IMP1 and IMP2 open reading frames, and part of the 30-
UTR of IMP3 were generated by nested RT-PCR from E12.5 mouse
embryonic RNA using the SuperscriptTM First-Strand system (Invit-
rogen), according to the conditions of the manufacturer. PCR-primer
sets: IMP1up1/IMP1low1, IMP2up1/IMP2low1 and IMP3up3/IM-
P3low3. Nested primer sets: IMP1up2/IMP1low2, IMP2up2/IM-
P2low2 and IMP3up5/IMP3low5. The IMP1 and IMP2 PCR-productswere ligated into pcDNA3.1/His (Invitrogen) (plasmids pJB19 and
pJB20). The IMP3-PCR-product was inserted into pcDNA3 (Invit-
rogen) (pJB24).
Wild-type HMGA2 and HMGA2Tr were generated by PCR from
the coding sequence of human HMGA2 as template using Pwo DNA
polymerase (Roche) according to the conditions of the manufacturer.
Primer sets: HMGA2up3/HMGA2low3 and HMGA2up3/HMGA2-
low5. The ampliﬁed DNA fragments were inserted into the retroviral
pMSCVpuro vector (Clontech) [23] (plasmids pJB13 and pJB15).
2.6. Hybridization probes and labeling
The IMP2 30-UTR-speciﬁc probe (position 1063–1606 bp behind the
stop codon) was obtained by digestion of AW542316. The IMP3 30-
UTR-speciﬁc probe was obtained by digestion of pJB24. The IMP1-
and HMGA2 CDS-speciﬁc probes were generated by digestion of
pJB19 and pJB13, respectively. The mouse b-actin probe was obtained
by PCR with primers Actin-up and Actin-low on E12.5 embryonic
cDNA. Probes were labeled with [a-32P]dCTP using the megaprime
DNA labeling system (Amersham) according to the manufacturer’s
conditions.
2.7. Cell culture, generation of retroviraly transduced NIH/3T3 cells
Cell lines included 293T (ATCC CRL-1573 human embryonic kid-
ney epithelial cells expressing SV40 T-antigen) and NIH/3T3 (mouse
embryo ﬁbroblast cells; ATCC CRL-1658). Cells were grown as de-
scribed [24]. Retroviraly transduced NIH/3T3 cell lines were obtained
as described in [25].
2.8. Antibody generation, SDS–PAGE and Western blotting
Polyclonal rabbit antiserum HMGA2ﬁx was raised against a mixture
of three synthetic peptides: 3ARGEGAGQPSTSAQGQPAAPAPQ
KR27, 59SPSKAAQKKAEATGEKR75 and 80PRKWPQQVVQKKP
AQEE96, synthesized as multiple-antigen peptide conjugates (Research
Genetics). Expression of HMGA2 and HMGA2Tr in recombinant
retrovirus transduced NIH/3T3 cells was veriﬁed by SDS–PAGE and
Western blotting as described [24], using HMGA2ﬁx antibody.3. Results and discussion
3.1. Identiﬁcation of HMGA2 downstream target genes with
strongly downregulated expression in HMGA2-deﬁcient
embryos
To identify highly downregulated downstream target genes
of HMGA2, we initially compared by microarray analysis the
gene expression proﬁle in embryos of the spontaneous pg/pg
mouse strain, which can be considered as a HMGA2 null
mutant strain, to that in corresponding wild-type embryos.
The developmentally regulated HMGA2 gene is only expressed
during embryogenesis and since its expression is readily de-
tected from stage E10.5 to stage E13.5 and decreases dra-
matically thereafter [9], we used RNA from whole embryos of
stage E12.5 in microarray analysis. One of the 8600 genes on
the microarray slides was HMGA2, represented by a clone
with GenBank Accession No. AW550862, which was consid-
ered as an internal, positive control. The microarray hybrid-
ization was performed a second time in a color ﬂip experiment.
The results of the microarray experiments revealed many
diﬀerentially expressed genes. As expected, the ratio between
the measured signal forHMGA2 (AW550862) in wild-type- and
the spontaneous pg/pg mutant embryos was high (Table 1). To
narrow down the list of diﬀerentially expressed genes in the
datasets, we selected those clones that had a signal ratio com-
parable to that of the positive control AW550862. This selec-
tion resulted in three additional clones (Table 1), AW548319
and AW542316, and an as yet not annotated clone. All other
diﬀerentially regulated genes displayed only a minor diﬀerence
in expression levels and are therefore not included in this study.
Table 1
Transcripts downregulated to the same extent as HMGA2 in E12.5 pg/pg mouse embryos
GenBank No. Gene description WT/pg ratio WT/pg ratio color ﬂip WT/pg ratio average
AW550862 Hmga2 71.42 80.04 75.73
AW548319 Hmga2 56.61 71.56 64.08
Unknown Hmga2 19.25 41.44 30.34
AW542316 Imp2 31.37 51.61 41.49
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search tool (BLAST) searches revealed that the not yet anno-
tated clone and AW548319 both corresponded to HMGA2.
The nucleotide sequence of the third clone, AW542316, was
similar to sequences of the 30-UTR of the human IMP2 gene,
indicating that AW542316 might correspond to the gene en-
coding mouse IMP2.
3.2. Downregulated clone AW542316 corresponds to mouse
IMP2
To establish that AW542316 indeed corresponds to mouse
IMP2, the complete mouse IMP2 cDNA sequence had to be
isolated, since at the time of our investigations, the contiguous
mouse IMP2 cDNA sequence was not yet available in the public
databases. Using the mouse EST database of the NCBI (Na-
tional Center for Biotechnology Information), a contig could be
generated covering the complete putative mIMP2 cDNA se-
quence containing part of the 50-UTR, the open reading frame,
the complete 30-UTR, including the AW542316 sequences, and
the poly(A)-tail. Subsequently, the complete mouse IMP2 open
reading frame was cloned by RT-PCR using E12.5 mouse em-
bryonic RNA with mIMP2-speciﬁc primers, sequenced, and its
nucleotide sequence was submitted to NCBI database (Gen-
Bank Accession No.: AY531659). Translation of the open
reading frame revealed an amino acid sequence that indeed re-
sembled most closely (about 94% sequence identity) the se-
quence of human IMP2 (Fig. 1A andB). In conclusion, results of
our studies so far clearly establish that it is IMP2 that is down-
regulated in E12.5 embryos of the pg/pg mouse mutant strain.
IMP2 belongs to a family of three IGF-II mRNA binding
proteins (IMP1, IMP2 and IMP3), which were found during a
search for trans-acting factors associating with IGF-II
mRNAs. Structurally, the IMP proteins are highly similar,
containing the unique combination of six characteristic RNA-
binding modules, two RNA recognition motifs (RRMs) [26]
and four hnRNP K homology (KH) domains [27] (Fig. 1).
IMP1 is orthologous to the chicken zipcode-binding protein
[28] and to the mouse c-myc coding region determinant-bind-
ing protein. IMP3 is identical to the KH-domain containing
protein overexpressed in cancer [29] and is orthologous to the
Vera protein in Xenopus laevis oocytes [30].
A splice variant of human IMP2, p62, missing 43 amino
acids located between KH-domains 2 and 3, was identiﬁed as
an autoantigen in human hepatocellular carcinoma [31]. RT-
PCR analysis (data not shown) indicated that the observed
downregulation of IMP2 expression in pg/pg mutant embryos
concerns only the IMP2 transcript, since the p62 transcript
could not be detected in wild-type E12.5 mouse embryos.
3.3. Diﬀerential downregulation of IMP family members in
E12.5 pg/pg mouse embryos
To conﬁrm the microarray results, we performed Northern
blot analysis of RNA isolated from pg/pg and correspondingwild-type mouse embryos. As expected, HMGA2 expression
was detected in wild-type but not in the pg/pg embryos
(Fig. 2A). Furthermore, IMP2 expression appeared to be be-
yond the detection level in the pg/pg embryos, whereas it was
clearly detectable in the wild-type embryos (Fig. 2A). Similar
Northern blot analysis using IMP1- or IMP3-speciﬁc probes
showed no detectable diﬀerences in IMP1 or IMP3 expression
levels in pg/pg embryos as compared to wild-type embryos
(Fig. 2B), establishing that only the expression of the IMP2
member of this gene family is aﬀected in pg/pg embryos. Fi-
nally, Northern blot analysis of RNA isolated from pg/pg and
corresponding wild-type newborn mice of 10 days old revealed
expression of low, but comparable, levels of IMP2 transcripts
in both strains. HMGA2 expression was clearly reduced in the
wild-type pups (data not shown).
3.4. IMP2 is a downstream target of HMGA2
A remaining issue pertains to the question whether IMP2 is
a downstream target of HMGA2. Genetically, the pg/pgmouse
is only partially characterized. A genomic region on chromo-
some 10 of more than 56 kb, encompassing the 50 sequences
and the ﬁrst two exons of HMGA2, is deleted [10]. To exclude
the possibility that the reason for IMP2 expression not being
detectable in Northern blot analyses is due to the fact that
IMP2 maps closely to HMGA2, and might therefore also be
deleted in pg/pg mice, the chromosomal mapping position of
IMP2 was determined. Mouse BLAST-Like Alignment Tool
search of the open reading frame of IMP2 against the UCSC
(University of California, Santa Cruz) Genome Browser re-
vealed, however, that the mouse IMP2 gene is located on
chromosome 16. The possibility still cannot be excluded that
IMP2 expression is regulated by another gene mapping to the
deleted region in pg/pg mice. To resolve this issue, we studied
IMP2 expression in HMGA2 null mutant mice generated via
targeted disruption of the HMGA2 gene [10]. Northern blot
analysis of RNA isolated from E12.5 HMGA2=,
HMGA2þ=, and HMGA2þ=þ embryos revealed that no
HMGA2 and very low levels of IMP2 transcripts could be
detected in the HMGA2= embryos (Fig. 3). In the
HMGA2þ= embryos, both HMGA2 and IMP2 expression
levels were clearly reduced as compared to the levels observed
in HMGA2þ=þ embryos (Fig. 3). No diﬀerences in expression
levels of the IMP2 family members, IMP1 and IMP3, could be
observed by performing similar Northern blot analysis (Fig. 3),
clearly revealing a diﬀerential regulation control within the
IMP family during embryogenesis.
These results point towards a prominent role for HMGA2 in
the regulation of IMP2 expression. Expression of IMP2 is bi-
phasic with an early expression in oocytes and in the zygote,
and a sharp increase in expression around embryonic day
E12.5, which declines towards birth [30]. In this respect,
HMGA2 and IMP2 display a somewhat similar expression
proﬁle during mouse embryogenesis. Our data, showing that
Fig. 1. Amino acid alignment of mouse IMP2 with all human IMP-family members. (A) Protein sequence alignment of hIMP1, hIMP2, hIMP3 and
mIMP2. The alignment was made using AlignX, a component of Vector NTI suite 8.0 software (InforMax, Inc). Amino acids identical to the ones in
mIMP2 are shown in gray. The two RRMs and four KH-domains are underlined [30]. (B) % Amino acid (AA) identity between all human and mouse
IMP-family members. Identity was calculated with AlignX.
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HMGA2= mice, indicate that HMGA2 is very likely to be
required for the sharp increase in expression of IMP2 at E12.5.
We have to note here that a very faint IMP2 signal was still
detected by Northern blot analysis of RNA isolated from
E12.5 HMGA2= mice (Fig. 3), indicating that very low ex-pression levels of IMP2 are still present in E12.5 HMGA2=
mice. These data indicate that, although HMGA2 plays a
prominent role in the regulation of IMP2-expression, other
factors must be involved too.
Functionally, the IMP proteins are capable of strong and
speciﬁc RNA-binding, and because of this, they have been
Fig. 2. Diﬀerential expression of IMP-family members in E12.5 pygmy
embryos. Northern blots, made with total RNA isolated from whole
E12.5 homozygous pygmy embryos and wild-type siblings, were hy-
bridized with an IMP2-speciﬁc 30-UTR probe (A), an HMGA2-speciﬁc
coding region probe (A), an IMP1-speciﬁc coding region probe (B), or
an IMP3-speciﬁc 30-UTR probe (B). The lower panel in each ﬁgure
shows rehybridization of the blots with a b-actin probe as control for
equal RNA-loading.
Fig. 3. IMP2 is a downstream target of HMGA2. Northern blots,
made with total RNA isolated from whole E12.5 HMGA2=,
HMGA2þ= and HMGA2þ=þ siblings, were hybridized with IMP2- or
IMP3-speciﬁc 30-UTR probes, or with HMGA2- or IMP1-speciﬁc
coding region probes. The lower panel shows rehybridization of the
blots with a b-actin probe as control for equal RNA-loading.
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localization, turnover and translational control. The three
human IMP proteins have been shown to speciﬁcally bind toIGF-II leader 3 mRNA (50-UTR), where they have an inﬂu-
ence on the translation of the mRNA into protein [30], and to
the 30 region of H19 RNA. To look whether Imp2 is involved
in the turnover of these RNAs, we looked for the expression
levels of Igf2 and H19 in the microarray dataset. However,
microarray analysis did not reveal a signiﬁcant change in ex-
pression levels of these genes.
Diﬀerent studies implicated the IMP proteins in temporal
and spatial control of gene expression at the level of mRNA
rather than at the level of gene transcription. In this regard, it
is tempting to speculate that the eﬀect of HMGA2 on cell
proliferation during embryonic development and tumorigene-
sis possibly involves IMP2. This also suggests that strong
downregulation of IMP2 expression at E12.5 in mice may
contribute to a pygmy phenotype.
Since IMP2 is drastically downregulated to nearly unde-
tectable levels in the E12.5 pygmy and HMGA2=-mice, an
IMP2 knockout mouse would further clarify the importance of
IMP2 deﬁciency in the HMGA2=phenotype. Because of the
drastic downregulation of IMP2 in the HMGA2 knockout
models, we could predict a similar growth retarded phenotype
for the IMP2= mouse, pointing to a very important role of
the HMGA2-IMP2 pathway in embryonic development. In
this regard, it is interesting to note that the recently published
Imp1-deﬁcient mice were on an average 40% smaller than wild-
type and heterozygous sex-matched littermates [32].
At present, not much is known about possible diﬀerences in
the function of the three IMP proteins. They are expressed in
the same time frame during embryonic development and since
it was shown that their major functions are carried out by the
phylogenetically conserved KH-domains [33], one could as-
sume that there is functional redundancy between the IMP
family members. However, from the observed diﬀerential
regulation during embryogenesis reported here, a ﬁrst indica-
tion seems to emerge, pointing towards functional diﬀerenti-
ation.
3.5. Eﬀect of a tumor-related aberrant form of HMGA2 on
IMP2 expression
With respect to tumorigenesis, the IMP proteins share var-
ious characteristics with HMGA2. They all are oncofetal
proteins that are highly expressed during embryonic develop-
ment, silenced during adult life, and misexpressed in diﬀerent
kinds of neoplasias [34]. Certain benign tumors are charac-
terized by chromosomal aberrations involving the HMGA2
gene [13,14]. Many of these tumors express a truncated form of
HMGA2 (HMGA2Tr), only containing the three DNA
binding domains and lacking the acidic and spacer domains
(Fig. 4A). Such a HMGA2Tr induces neoplastic transforma-
tion of NIH/3T3 murine ﬁbroblasts [35]. Transgenic mice ab-
errantly expressing this truncated HMGA2 protein present
gigantism that is associated with lipomatosis [36], develop
adiposity, and display an abnormal high prevalence of lipomas
[37]. To study the eﬀect of HMGA2Tr on IMP2, NIH/3T3 cell
lines overexpressing HMGA2 or HMGA2Tr were made by
retroviral transduction. Expression of HMGA2 and
HMGA2Tr was assayed by Western blot analysis with an
HMGA2-speciﬁc antibody (Fig. 4B, lanes 2 and 3). IMP2
expression levels were determined by Northern blot analysis.
In Fig. 4C and D, it is shown that HMGA2 upregulates IMP2
expression and this to an extent of about 124% of the level in
the control cells (Mock). However, HMGA2Tr appears to
Fig. 4. Eﬀect of a tumor-speciﬁc aberrant form of HMGA2 on IMP2 expression. (A) Schematic representation of wild-type HMGA2 and its tumor-
speciﬁc form HMGA2Tr (AT: AT-hook, AD: acidic domain). (B) Western blot analysis of cell lysates of NIH/3T3 stable cell lines overexpressing
wild-type HMGA2 or HMGA2Tr, using the HMGA2ﬁx antibody. (C) Representative Northern blot of RNA extracted from the NIH/3T3 stable cell
lines hybridized with an IMP2-speciﬁc 30-UTR probe . The lower panel shows rehybridization of the blot with a b-actin probe as control for equal
RNA-loading. (D) Graph depicting quantiﬁcation of IMP2 mRNA levels of the Northern blot analyses. The results are given as a percentage of
Mock (NIH/3T3 infected with empty vector) after normalization to b-actin. The results are shown as the average of three independent experiments.
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control cells (Mock). Similar results were obtained by com-
paring mRNA expression levels between HMGA2Tr-overex-
pressing and control NIH/3T3 cells by microarray analysis
(our unpublished observations). Similar Northern blot analysis
with probes speciﬁc for IMP1 and IMP3 revealed no diﬀerence
in the expression levels of these genes (results not shown).
These experiments indicate that the HMGA2Tr that is fre-
quently expressed in benign solid tumors exerts a diﬀerential,
negative eﬀect on expression of members of the IMP gene
family and point to the potential signiﬁcance of the HMGA2-
IMP2 pathway being deregulated in these tumors. Our results
also suggest that the acidic tail of HMGA2 plays a role in the
transcriptional regulation of target genes. Recently, Noro et al.
[38] showed that the acidic tail of HMGA2 is not involved in
determining the HMGA2 DNA-binding speciﬁcity, but can
alter HMGA2/DNA complexes. Their results suggested that
wild-type HMGA2 and HMGA2Tr could have the same target
genes, but a diﬀerential regulating eﬀect, in agreement with the
results presented here. To resolve the question as to whetherthe HMGA2-IMP2 pathways are involved in tumor develop-
ment, IMP2 expression levels can be assessed in tumors with
aberrant expression of HMGA2.
In any case, the diﬀerential eﬀect of wild-type HMGA2 on
IMP gene expression during mouse embryogenesis constitutes
a new opening for the functional dissection of the latter gene
family.
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